Undisclosed Cell Envelope Program(s)
Infections by multidrug-resistant Gram-negative and Gram-positive bacteria
Pre-clinicalActive
Key Facts
Indication
Infections by multidrug-resistant Gram-negative and Gram-positive bacteria
Phase
Pre-clinical
Status
Active
Company
About Prokaryotics
Prokaryotics is a private, pre-clinical biotech startup tackling the global antibiotic resistance crisis by developing new classes of antibiotics that target Gram-negative and Gram-positive bacteria. The company's strategy centers on inhibiting cell envelope assembly, a fundamental and conserved bacterial process, to overcome intrinsic resistance mechanisms. Founded by ex-Merck antimicrobial discovery leaders, Prokaryotics leverages licensed assets, deep physiological expertise, and innovative screening to advance its pipeline.
View full company profile